ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Exploring the molecular function of LYPD3 from pan-cancer to lung cancer: based on bioinformatics and cellular experiments.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Pan-Cancer Analysis of ABCA1: Insights From Multi-Omics Data and Exploratory Validation in Esophageal Squamous Cell Carcinoma.Cell biochemistry and function · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As a major disease that seriously threatens human health, the prevention and control of malignant tumors has become an important challenge for global public health. In this study, we first investigated the expression level, prognostic value, and diagnostic value of LYPD3 in pan-cancer, and its effects on the immune microenvironment, genetic variation, and antitumor drug sensitivity. RT-PCR and western blot were used to detect the transfection efficiency. Cell apoptosis was detected by flow cytometry. Transwell assay for detection of cell invasion and migration. Western blot was used to detect the expression of Bax, Bcl-2, E-cadherin, N-cadherin and Vimentin. LYPD3 showed high expression in lung cancer, both at the mRNA and protein level. Single-cell transcriptome and spatial transcriptomics reveal that LYPD3 is highly expressed in tumor cells and tumor-associated fibroblasts. ROC analysis revealed that LYPD3 exhibited significant diagnostic efficacy in pan-cancer, and Cox regression analysis revealed that LYPD3 expression was significantly associated with the risk of death in certain cancer types. LYPD3 has a good diagnostic value and prognostic predictive value in pan-cancer. GDSC and CTRP data analysis confirmed that LYPD3 expression was negatively correlated with the drug sensitivity of lapatinib, erlotinib, and afatinib. Focusing on the expression of LYPD3 in lung cancer, cellular experiments revealed that LYPD3 promotes lung cancer cell invasion and metastasis while inhibiting apoptosis. Meanwhile, LYPD3 has a good diagnostic value and prognostic prediction value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.